DALLAS, September 18, 2014 /PRNewswire/ --
Research Report on Hemodialysis Industry in China, 2014-2018 is a new market intelligence study of 50 pages, published in September 2014 and now available with LifeScienceIndustryResearch.com. As Chinese economy develops with increasing income per capita and payment ability of hemodialysis patients, the industry will develop rapidly in the future. The costs of hemodialysis consist of instruments, drugs and services with the proportions of 45%, 25% and 30% respectively. Complete report can be accessed at http://www.lifescienceindustryresearch.com/research-report-on-hemodialysis-industry-in-china-2014-2018.html .
The Research Report on Hemodialysis Industry in China, 2014-2018 says hemodialysis (also HD) is one of the replace therapy for patients with acute and chronic renal failure. There are globally 2.2 million uremia patients (end stage renal disease, ESRD) receiving dialysis treatment, including over 89% of them receiving hemodialysis. As the cost of hemodialysis is high, most dialysis patients are concentrated in developed regions like Europe and the U.S. The dialysis patients are fewer in developing countries but increases rapidly. In recent years, the growth rate of dialysis patients in China, India and Brazil remains above 15%, much higher than 3%-5% in Europe and the U.S. Meanwhile, the proportion of ESRD patients that receive dialysis treatment is only 10%-20% in developing countries, much lower than 80% in Europe and the U.S.A.
Hemodialysis instruments industry includes dialysis machines, dialyzer and dialysis pipelines. Dialyzers are core supplies with high technical barriers and account for the largest market shares. The market size in China exceeds CNY 5 billion while the domestic market share is approximately 30%. More domestic products become substitutes of imports. The dialysis machine market is dominated by foreign-funded brands, which belong to one-time investment in the earlier stage. Conventional medicines of hemodialysis include EPO and heparin, which are basically domestically produced. Service costs include costs of bed and health care labors. The three major operation modes of domestic private hemodialysis centers include independent hemodialysis centers, cooperation with hospitals and investment in instruments.
The market size of Chinese hemodialysis market exceeded CNY 20 billion in China in 2013 with the annual growth rate of 20%-30%. Instruments, drugs and services are three major factors of the hemodialysis market, also the three entry points of the industry chain. By 2020, the global ESRD patients receiving hemodialysis treatment will reach 4.2 million while that in China will surpass 1 million. The market size of Chinese hemodialysis market is expected to exceed CNY 70 billion in China by 2020 with the CAGR above 20%. Meanwhile, the market size of auxiliary drugs will exceed CNY 60 billion. Order a copy of this report (US$ 1800 single user PDF) at http://www.lifescienceindustryresearch.com/purchase?rname=22860 .
Readers can obtain the following information or more through Research Report on Hemodialysis Industry in China, 2014-2018:
-Status of Hemodialysis Market in China
-Economic Environment and Policy Environment for China Hemodialysis Market
-Major Suppliers of Equipment and Consumables in China Hemodialysis Market
-Competition Status of China Hemodialysis Market
-Driving Factors for Development of China Hemodialysis Market
-Forecast on Development of China Hemodialysis Market
The following enterprises and people are recommended to purchase Research Report on Hemodialysis Industry in China, 2014-2018:
-Medical Institutions
-Manufacturers of Medical Equipment and Drugs
-Trading Enterprises of Medical Equipment and Drugs
-Investors and Research Institutions Concerned about Hemodialysis Market
Companies profiled in this Chinese hemodialysis market report include Fresenius SE & Co. KGaA, Nipro Co.,Ltd., Baxter International, Asahi Kasei Corporation, Weigao Group, Huaren Pharmaceutical Co., Ltd.¸ Guangdong Biolight Meditech Co., Ltd., Sichuan Kelun Pharmaceutical Co., Ltd., Jihua Medical Apparatus and Instruments Co., Ltd. and Bain Medical Equipment (Guangzhou) Co., Ltd. Comprehensive Table of Contents and more on this research is available at http://www.lifescienceindustryresearch.com/research-report-on-hemodialysis-industry-in-china-2014-2018.html#tabs-2 .
Another report titled China PTCA Balloon Market Investment Report, 2014-2016 is spread across 114 pages and was published in September 2014. In 2013, 309.42 per 1 million were people receiving PCI treatment in China, compared with 1800 cases in the United States, showing a vast space for development of the Chinese PCI market and a bright future for PTCA balloon industry. It is expected that China's demand for PTCA balloon will hit 1.824 million sets by 2016. Companies profiled in this research include Lepu Medical, MicroPort, JW Medical, Dalian Yinyi, Neich Medical (Shenzhen), SCW Medicath, Synexmed, Sino Medical, Demax Medical (Beijing), Medtronic, Boston Scientific, Abbott, Terumo and B. Braun Melsungen.
Explore more reports on the medical devices industry at http://www.lifescienceindustryresearch.com/category/medical-devices .
About Us:
Life Science Industry Research brings to you to the latest reports in market research on Biotechnology, Diagnostics, Healthcare, Medical Devices and Pharmaceuticals segments from leading research publishers across the globe. These reports also cover data and information on sub-segments and sectors under these life sciences categories.
Contact: Ritesh Tiwari TX, Dallas North - Dominion Plaza 17304, Preston Road, Suite 800, Dallas 75252 Tel: +1-888-391-5441 [email protected]
Connect With Us on:
Twitter: https://twitter.com/LifeSciReports G+ / Google Plus: https://plus.google.com/112612135957880308475/about RSS Feed: http://www.lifescienceindustryresearch.com/feed
SOURCE Life Science Industry Research
Research Report on Hemodialysis Industry in China, 2014-2018 is a new market intelligence study of 50 pages, published in September 2014 and now available with LifeScienceIndustryResearch.com. As Chinese economy develops with increasing income per capita and payment ability of hemodialysis patients, the industry will develop rapidly in the future. The costs of hemodialysis consist of instruments, drugs and services with the proportions of 45%, 25% and 30% respectively. Complete report can be accessed at http://www.lifescienceindustryresearch.com/research-report-on-hemodialysis-industry-in-china-2014-2018.html .
Advertisement
The Research Report on Hemodialysis Industry in China, 2014-2018 says hemodialysis (also HD) is one of the replace therapy for patients with acute and chronic renal failure. There are globally 2.2 million uremia patients (end stage renal disease, ESRD) receiving dialysis treatment, including over 89% of them receiving hemodialysis. As the cost of hemodialysis is high, most dialysis patients are concentrated in developed regions like Europe and the U.S. The dialysis patients are fewer in developing countries but increases rapidly. In recent years, the growth rate of dialysis patients in China, India and Brazil remains above 15%, much higher than 3%-5% in Europe and the U.S. Meanwhile, the proportion of ESRD patients that receive dialysis treatment is only 10%-20% in developing countries, much lower than 80% in Europe and the U.S.A.
Advertisement
Hemodialysis instruments industry includes dialysis machines, dialyzer and dialysis pipelines. Dialyzers are core supplies with high technical barriers and account for the largest market shares. The market size in China exceeds CNY 5 billion while the domestic market share is approximately 30%. More domestic products become substitutes of imports. The dialysis machine market is dominated by foreign-funded brands, which belong to one-time investment in the earlier stage. Conventional medicines of hemodialysis include EPO and heparin, which are basically domestically produced. Service costs include costs of bed and health care labors. The three major operation modes of domestic private hemodialysis centers include independent hemodialysis centers, cooperation with hospitals and investment in instruments.
The market size of Chinese hemodialysis market exceeded CNY 20 billion in China in 2013 with the annual growth rate of 20%-30%. Instruments, drugs and services are three major factors of the hemodialysis market, also the three entry points of the industry chain. By 2020, the global ESRD patients receiving hemodialysis treatment will reach 4.2 million while that in China will surpass 1 million. The market size of Chinese hemodialysis market is expected to exceed CNY 70 billion in China by 2020 with the CAGR above 20%. Meanwhile, the market size of auxiliary drugs will exceed CNY 60 billion. Order a copy of this report (US$ 1800 single user PDF) at http://www.lifescienceindustryresearch.com/purchase?rname=22860 .
Readers can obtain the following information or more through Research Report on Hemodialysis Industry in China, 2014-2018:
-Status of Hemodialysis Market in China
-Economic Environment and Policy Environment for China Hemodialysis Market
-Major Suppliers of Equipment and Consumables in China Hemodialysis Market
-Competition Status of China Hemodialysis Market
-Driving Factors for Development of China Hemodialysis Market
-Forecast on Development of China Hemodialysis Market
The following enterprises and people are recommended to purchase Research Report on Hemodialysis Industry in China, 2014-2018:
-Medical Institutions
-Manufacturers of Medical Equipment and Drugs
-Trading Enterprises of Medical Equipment and Drugs
-Investors and Research Institutions Concerned about Hemodialysis Market
Companies profiled in this Chinese hemodialysis market report include Fresenius SE & Co. KGaA, Nipro Co.,Ltd., Baxter International, Asahi Kasei Corporation, Weigao Group, Huaren Pharmaceutical Co., Ltd.¸ Guangdong Biolight Meditech Co., Ltd., Sichuan Kelun Pharmaceutical Co., Ltd., Jihua Medical Apparatus and Instruments Co., Ltd. and Bain Medical Equipment (Guangzhou) Co., Ltd. Comprehensive Table of Contents and more on this research is available at http://www.lifescienceindustryresearch.com/research-report-on-hemodialysis-industry-in-china-2014-2018.html#tabs-2 .
Another report titled China PTCA Balloon Market Investment Report, 2014-2016 is spread across 114 pages and was published in September 2014. In 2013, 309.42 per 1 million were people receiving PCI treatment in China, compared with 1800 cases in the United States, showing a vast space for development of the Chinese PCI market and a bright future for PTCA balloon industry. It is expected that China's demand for PTCA balloon will hit 1.824 million sets by 2016. Companies profiled in this research include Lepu Medical, MicroPort, JW Medical, Dalian Yinyi, Neich Medical (Shenzhen), SCW Medicath, Synexmed, Sino Medical, Demax Medical (Beijing), Medtronic, Boston Scientific, Abbott, Terumo and B. Braun Melsungen.
Explore more reports on the medical devices industry at http://www.lifescienceindustryresearch.com/category/medical-devices .
About Us:
Life Science Industry Research brings to you to the latest reports in market research on Biotechnology, Diagnostics, Healthcare, Medical Devices and Pharmaceuticals segments from leading research publishers across the globe. These reports also cover data and information on sub-segments and sectors under these life sciences categories.
Contact: Ritesh Tiwari TX, Dallas North - Dominion Plaza 17304, Preston Road, Suite 800, Dallas 75252 Tel: +1-888-391-5441 [email protected]
Connect With Us on:
Twitter: https://twitter.com/LifeSciReports G+ / Google Plus: https://plus.google.com/112612135957880308475/about RSS Feed: http://www.lifescienceindustryresearch.com/feed
SOURCE Life Science Industry Research
